Project Grant R56DK140174
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $168,900 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. This grant, awarded on Jul 15, 2025, supports research to determine how the commensal bacterial species Blautia activates signaling events within the gut epithelium to benefit host metabolism and mucosal health....
- This $108,486 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to identify novel immune markers associated with obesity-driven diseases. The objective is to utilize novel tools to study the inter-organ communication pathway between the intestine and adipose tissue immune cells. The research leverages a Cre-inducible...
- The Beckman Research Institute of the City of Hope received a $140,116 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant, awarded on September 15, 2025, will support research to identify and characterize a mechanism of communication between the intestine and white adipose tissue via intestinal mTOR signaling. The goal is to understand how...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $773,112 Project Grant to Rockefeller University on September 5, 2025 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to investigate the mechanisms of transcriptional control in adipocyte formation and function through nuclear receptor coactivators. The research aims to provide a better understanding of dysregulation in energy storage...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,255,725 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Icahn School of Medicine at Mount Sinai. The funding will support the development of a solid-state fermentation platform for manufacturing defined live biotherapeutic products (LBPs) comprised of in vitro manufactured bacterial strains. This represents a scalable approach to...
- This federal Project Grant award of $802,843, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research conducted by Yale University to investigate the relationship between intestinal microbial activity and human metabolism. The key objectives are to: 1) understand how insulin resistance affects the adipose tissue lipolysis response to intestinal...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,778,953 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Regents of the University of Minnesota. The award, with a start date of September 16, 2025 and a completion date of June 30, 2029, will support research on the dynamics of the HIV reservoir and its association with metabolic complications of HIV infection in individuals receiving...
- This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research focused on understanding the mechanisms that regulate lipid flux in cells and animals, and how crosstalk between gut immune cells and the absorptive epithelium impacts metabolic disease. The $761,399 award, effective September 1, 2025 through June 30, 2030, will...
- This federal Project Grant award of $458,047.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to understand how extracellular vesicles (EVs) from intestinal epithelial cells (enterocytes) mediate cell-to-cell communication and function as effectors of inflammation in inflammatory bowel disease (IBD). Specific objectives include identifying...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Duke University a $241,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to study the regulation of metabolic diseases by the human commensal bacterium Clostridium immunis. The overarching goal is to determine the mechanism by which an exopolysaccharide (EPS) secreted by C. immunis decreases visceral adiposity, a key risk factor for type 2 diabetes and metabolic syndrome. The proposed research aims to analyze energy balance under relevant environmental conditions and investigate the immunomodulatory effects of the C. immunis EPS, which may reduce visceral adipose tissue via decreasing IL-22 production by group 3 innate lymphoid cells. This foundational research is expected to provide insights into microbiome-immune-metabolism interactions and highlight new microbiome-derived therapeutic opportunities for treating visceral adiposity and associated complications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $241.5k | 7/23/24 |